

ASTRAZENECA PLC  
Form 6-K  
September 28, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of September 2018

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82- \_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

1.  
Previous Announcement Regarding Appointment Of NED

28 September 2018 16:00 BST

PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NON-EXECUTIVE DIRECTOR

AstraZeneca PLC (the Company) today announced that with the Company's agreement, Joseph G. Peter (Joe Peter) has withdrawn his candidacy as a Non-Executive Director and a member of the Audit Committee. His proposed appointment to these positions was announced by the Company on 6 September 2018 and was to have become effective on 1 October 2018. Mr Peter's decision is for reasons that are not related to the Company.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

Media Relations

|                  |           |                        |
|------------------|-----------|------------------------|
| Karen Birmingham | UK/Global | +44 203<br>749 5634    |
| Rob Skelding     | UK/Global | +44 203<br>749 5821    |
| Matt Kent        | UK/Global | +44 203<br>749 5906    |
| Gonzalo Viña     | UK/Global | +44 203<br>749 5916    |
| Jacob Lund       | Sweden    | +46<br>8 553 260<br>20 |
| Michele Meixell  | US        | +1 302<br>885 2677     |

Investor Relations

|                     |          |                     |
|---------------------|----------|---------------------|
| Thomas Kudsk Larsen |          | +44 203<br>749 5712 |
| Henry Wheeler       | Oncology | +44 203<br>749 5797 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                    |                            |                     |
|--------------------|----------------------------|---------------------|
| Christer Gruvris   | Cardiovascular; Metabolism | +44 203<br>749 5711 |
| Nick Stone         | Respiratory; Renal         | +44 203<br>749 5716 |
| Josie Afolabi      | Other                      | +44 203<br>749 5631 |
| Craig Marks        | Finance; Fixed Income      | +44 7881<br>615 764 |
| Jennifer Kretzmann | Retail Investors           | +44 203<br>749 5824 |
| US toll-free       |                            | +1 866<br>381 7277  |

Adrian Kemp  
Company Secretary  
AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 September 2018

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary